Life Sciences Tools and Services
Company Overview of Cancer Research Technology Limited
Cancer Research Technology Limited operates as a cancer-focused drug discovery, technology transfer, and commercialization company. It develops and licenses oncology related opportunities with pharmaceutical and biotechnology companies; and translates academic discoveries into industrial propositions. The company engages in sourcing and developing cancer discoveries; providing technology transfer services to cancer researchers; and identifying scientific and business solutions to unmet needs in cancer. Its drug discovery programs include the identification of small molecule inhibitors against various target classes, including kinases, kinesins, methyltransferases, and molecular chaperone tar...
407 St John Street
London, EC1V 4AD
Founded in 1982
Key Executives for Cancer Research Technology Limited
Chief Executive Officer and Director
Chief Operating Officer and Chief Executive of Cancer Research UK
Head of Medicinal Chemistry
Head of Molecular Pharmacology, Biochemistry & High Throughput Screening
Head of Clinical Partnerships
Compensation as of Fiscal Year 2015.
Cancer Research Technology Limited Key Developments
Cancer Research Technology Limited Enters License Agreement with Merck & Co., Inc
Jan 28 16
Cancer Research Technology Limited (CRT) has entered into a license agreement with Merck & Co. Inc. (MSD) to develop inhibitors of protein arginine methyltransferase 5 (PRMT5). CRT has licensed rights to MSD on behalf of Cancer Therapeutics (CTx). Under the terms of the license, MSD will be responsible for research and development, including clinical development, and for worldwide commercialization of products. As part of the research and development activities, MSD has entered into a research collaboration with CTx focusing on blood disorders, which MSD will fund. CRT will receive an upfront payment of $15 million and is eligible to receive potential payments of up to $500 million for achievement of development, regulatory and commercialization milestones. In addition, the agreement provides for royalties on sales.
Forma Therapeutics and Cancer Research Technology Form A Third Virtual Company to Advance Deubiquitination Assets
Jan 12 16
FORMA Therapeutics and Cancer Research Technology Ltd. announced the formation of a third new virtual Asset Discovery and Development Company with novel chemical matter targeting an undisclosed deubiquitinating enzyme (DUB). ADDCos are virtual companies that rapidly advance drug discovery innovations in a compelling scientific area through the collaboration of academic thought leaders, FORMA drug discovery scientists and a world class development network. Under the agreement, FORMA is pairing its ultra-efficient drug discovery and early development capabilities with expertise from CRT’s Discovery Laboratories (CRT-DL) and the exclusive world-class academic network of Cancer Research UK scientists.
Cell Therapy Catapult, University of Birmingham and Cancer Research Technology Launch New Collaboration for CAR-T Cell Immuno-Oncology Therapy Development
Jan 6 16
The Cell Therapy Catapult, the University of Birmingham and Cancer Research Technology, the commercialization arm of Cancer Research UK, announced the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours. The project is aimed at translating an academic discovery programme funded by Cancer Research UK and developed by Dr. Steven Lee and Prof Roy Bicknell at the University of Birmingham into a commercially viable cell therapy. The collaborating partners have launched a new company, Chimeric Therapeutics Ltd. This new company will hold all future IP rights to the resultant discoveries. The project is based on a new generation chimeric antigen receptor T-Cell (CAR-T) immuno-oncology therapy for solid tumours. This involves directing the CAR-T cell towards a new, highly specific marker of tumour angiogenesis, CLEC14a. This therapy will act as a vasculature disruptive agent compromising oxygen supply to the tumours and inhibiting tumour growth. The technology is currently undergoing the final stages of preclinical development, and is planned to enter into clinical trials soon after. Cancer Research Technology and the University of Birmingham have partnered with The Cell Therapy Catapult to bring their extensive regulatory, clinical, analytical and manufacturing process development expertise into the program, utilizing their experience in developing immunotherapies for cancer. The Cell Therapy Catapult will specifically be involved in the project to accelerate the translation of the academic discoveries made in Birmingham with Cancer Research Technology around CAR-T immunotherapies for solid tumours and the CLEC14a target towards a commercially available cell therapy.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|